Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Takeda Pharmaceutical Ltd ADR
(NY:
TAK
)
13.53
-0.17 (-1.24%)
Streaming Delayed Price
Updated: 1:25 PM EDT, Jul 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Takeda Pharmaceutical Ltd ADR
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
Worldwide Adoption of Novavax Vaccines Makes It a Winner
January 21, 2022
Novavax can still generate billions of dollars of revenue per year from its shot, making NVAX stock quite attractive at its current levels.
Via
InvestorPlace
Takeda Named Global Top Employer for Fifth Consecutive Year
January 19, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
More Serious Matters
January 14, 2022
Wall Street fell on new worries about inflation and a drop in retail sales levels.
Via
Talk Markets
Denali Stock Tumbles; Why Biogen Isn't The Only Alzheimer's Play Under Pressure
January 13, 2022
Denali Therapeutics is under pressure after the FDA put its study on hold.
Via
Investor's Business Daily
Interest Rate Hikes And Stocks
January 12, 2022
Abnormal flooding in northwest Brazil has blocked iron ore mining which resulted in a jump in the price of ore.
Via
Talk Markets
Takeda Emphasizes Strategy for Delivering Sustainable Growth Over Next Decade at the 40th Annual J.P. Morgan Healthcare Conference
January 10, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (γδ) T Cell Engager Therapies Targeting Solid Tumors
January 10, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Post-Fed Thursday
January 06, 2022
Companies earning in dollars but incorporated abroad and paying dividends in other currencies were big gainers today.
Via
Talk Markets
FDA Rejects Takeda's Eosinophilic Esophagitis Candidate, Asks For Additional Study
December 22, 2021
Takeda Pharmaceutical Co Ltd (NYSE: TAK) received a Complete Response Letter (CRL) from the FDA for its marketing application for TAK-721 (budesonide oral...
Via
Benzinga
The Daily Biotech Pulse: Allakos Slips Negative Late-Stage Data, Pfizer & Merck Announce Fresh COVID Pill Deal With UK, Regulatory Setback For Takeda
December 22, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Allakos's Lirentelimab Flunks Late-Stage Studies In Patients With...
Via
Benzinga
Takeda Receives Complete Response Letter from the U.S. FDA for TAK-721
December 21, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Systemic Mastocytosis Treatments Gain Hope Due To Increasing Novel Treatment Options
December 21, 2021
Palm Beach, FL –December 21, 2021 – FinancialNewsMedia.com News Commentary – Systemic mastocytosis is rare disease which affects very few people and it causes due to C-kit mutation which leads to...
Via
FinancialNewsMedia
Exposures
Product Safety
The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street
December 16, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Calliditas Gets Conditional Approval For Kidney Inflammation Disease Drug...
Via
Benzinga
Novavax Files For Approval Of Its COVID-19 Vaccine In Japan
December 16, 2021
Novavax Inc (NASDAQ: NVAX) has submitted a marketing application in Japan seeking approval for its COVID-19 vaccine by its partner Takeda Pharmaceutical Co Ltd...
Via
Benzinga
3 Stocks That Can Make You Rich in Just a Few Years
December 14, 2021
Investing in the most popular stocks on the Street won't make investors rich in a few years. To accomplish that goal, a contrarian spirit is needed.
Via
InvestorPlace
Comparing Data: Sanofi Vs. Johnson & Johnson Multiple Myeloma Therapies In Newly Diagnosed Patients
December 13, 2021
Sanofi SA (NASDAQ: SNY) and Johnson & Johnson (NYSE: JNJ) posted new data from their myeloma therapies, Sarclisa and Darzalex, respectively. Data were shared at...
Via
Benzinga
Takeda Drives Continued Scientific Leadership Through Real-World Evidence in Rare Hematological Diseases at ASH 2021
December 13, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces Publication of Data from SOLSTICE, a Pivotal Phase 3 Trial for LIVTENCITY™ (Maribavir) in Post-Transplant Recipients With Cytomegalovirus (CMV) Infection (Refractory, With or Without Resistance)
December 08, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts
December 07, 2021
These seven drug stocks, a mix of growth, value, and moonshot plays, each stand to see big moves in the next twelve months.
Via
InvestorPlace
Exposures
COVID-19
Takeda Unveils New Research to Advance Patient Care in Hematology and Oncology at 63rd American Society of Hematology (ASH) Annual Meeting
December 07, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda’s LIVTENCITY™ (maribavir) Now Available for Certain Individuals Ages 12 Years and Older With Post-Transplant Cytomegalovirus (CMV) Infection/Disease in the United States
December 02, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Happy December
December 01, 2021
Inflation levels this year will almost certainly lower growth in 2022 because of inflation this year in everything from house prices....to stock prices.
Via
Talk Markets
Takeda Announces U.S. Corporate Social Responsibility (CSR) Program Aimed to Help Reduce Social Disparities
November 30, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, & More
November 28, 2021
Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant helped mitigate the losses notched earlier in the holiday-shortened week.
Via
Talk Markets
Exposures
COVID-19
Product Safety
The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, BeyondSpring, CTI Biopharma And Merck Take The Spotlight In A Light Calendar Week
November 28, 2021
Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant, named Omicron, helped mitigate the losses...
Via
Benzinga
Exposures
COVID-19
Product Safety
The Daily Biotech Pulse: Kura's Blood Cancer Drug Study Gets Partial Clinical Hold, Takeda FDA Nod, Puma Breast Cancer Treatment Gets Patent Extension
November 24, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Puma Biotech Announces Receipt Of Patent Extension For Breast Cancer Drug By...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Takeda's Maribavir Scores FDA Approval For Post-Transplant CMV Infection
November 24, 2021
The FDA has approved Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Livtencity (maribavir) for a common type of viral infection occurring in patients after...
Via
Benzinga
Exposures
Product Safety
Takeda’s LIVTENCITYTM (maribavir) Approved by U.S. FDA as the First and Only Treatment for People Ages 12 and Older with Post-Transplant Cytomegalovirus (CMV), Refractory (With or Without Genotypic Resistance) to Conventional Antiviral Therapies
November 23, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
The Daily Biotech Pulse: Arrowhead Out-Licenses NASH Drug, Tonix Touts COVID-19 Treatment Data, Aadi Jumps On FDA Nod For Rare Tumor Drug
November 23, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Synlogic Presents Positive Phase 2 Data For Synthetic Biologic Treatment In...
Via
Benzinga
Exposures
COVID-19
Product Safety
The Week Ahead In Biotech (Nov. 21-Nov. 27): FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
November 21, 2021
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reporting...
Via
Talk Markets
Exposures
Product Safety
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.